000			02010 a2200481 4500
005			20250511225224.0
264		0	_c19910308
008			199103s 0 0 eng d
022			_a1045-2257
024	7		_a10.1002/gcc.2870020110 _2doi
040			_aNLM _beng _cNLM
100	1		_aAlbain, K S
245	0	0	_aImplication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation. _h[electronic resource]
260			_bGenes, chromosomes & cancer _cMay 1990
300			_a53-8 p. _bdigital
500			_aPublication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
650	0	4	_aAlkylating Agents _xadverse effects
650	0	4	_aAntibiotics, Antineoplastic _xadverse effects
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBreast Neoplasms _xcomplications
650	0	4	_aChromosomes, Human, Pair 11 _xultrastructure
650	0	4	_aChromosomes, Human, Pair 9 _xultrastructure
650	0	4	_aCisplatin _xadverse effects
650	0	4	_aCombined Modality Therapy
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aDactinomycin _xadverse effects
650	0	4	_aDoxorubicin _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aIatrogenic Disease
650	0	4	_aLeukemia, Monocytic, Acute _xchemically induced
650	0	4	_aMastectomy, Radical
650	0	4	_aMiddle Aged
650	0	4	_aPodophyllotoxin _xadverse effects
650	0	4	_aRadiotherapy
650	0	4	_aTamoxifen _xadministration & dosage
650	0	4	_aTopoisomerase II Inhibitors
650	0	4	_aTranslocation, Genetic
700	1		_aLe Beau, M M
700	1		_aUllirsch, R
700	1		_aSchumacher, H
773	0		_tGenes, chromosomes & cancer _gvol. 2 _gno. 1 _gp. 53-8
856	4	0	_uhttps://doi.org/10.1002/gcc.2870020110 _zAvailable from publisher's website
999			_c2183770 _d2183770